Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?

As far as I know, there is no data on the repeat use of mirvetuximab for women who have progressed on prior treatment. I would tend to use cytotoxic therapy in this setting, but if the patient tolerated it well previously and has a good performance status, a short trial of repeat mirvetuximab seems ...

Agree with Dr. @Dr. First Last. Discontinuation due to progression is probably different from discontinuation due to other events, especially if there was documentation of response. I have personally retreated patients with FRa high expression with mirvetuximab and discontinued treatment due to some...